Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alternative Splicing Yields Insights Into Cancer Metabolism And Potential New Drug Targets

This article was originally published in Start Up

Executive Summary

For the first time, cancer researchers have shown that a variant of the EGF receptor often amplified in glioblastoma upregulates a specific splicing protein that in turn alters cancer metabolism. This increased understanding of the factors controlling so-called “alternative splicing” could offer up a range of new therapeutic approaches in GBM, other cancers, and potentially other diseases.

You may also be interested in...



R&D Realities Disturb Dreams About Orphan Brain Cancer Blockbusters

Developing drugs for the rare, aggressive glioblastoma, the most common and malignant type of glioma, or brain cancer, was never easy. But a brain cancer drug’s journey through Phase III and to the finish line of market entry today is more arduous than ever.

Science Matters: With Ferroptosis, Cancer Drug Developers Can Strike While Iron Is Hot

A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.

Science Matters: Glimmers Of Hope For Treating ALS

Recent clinical data using antisense drugs in neurological diseases are encouraging signs that targeting genetic drivers of ALS with antisense oligonucleotides or other gene-altering drugs could halt progression of several forms of the disease.

Topics

Related Companies

UsernamePublicRestriction

Register

SC092481

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel